Global Covid-19 Treatment Market Size, Status and Forecast 2022

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In this report, we study all treatment method for Covid-19.
Global core covid-19 treatment manufacturers include Cadila Healthcare, Novartis etc.The top 2 companies hold a share about 30%.North America is the largest market, with a share about 47%, followed by Europe and Asia Pacific with the share about 30% and 9%.

Market Analysis and Insights: Global Covid-19 Treatment Market
The global Covid-19 Treatment market size is projected to reach US$ 64 million by 2027, from US$ 14440 million in 2020, at a CAGR of -59.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Covid-19 Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Covid-19 Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Covid-19 Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Covid-19 Treatment market.

Global Covid-19 Treatment Scope and Market Size
Covid-19 Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Covid-19 Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by End User in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Life Support
Antiviral Medicine
Antibody Treatments
Others

Segment by End User
Children
Adult

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Cadila Healthcare
Johnson & Johnson
ImmunoPrecise
Novartis
AstraZeneca
Cipla
AbbVie
Bayer
Regeneron Pharmaceuticals
Ascletis Pharma
GlaxoSmithKline
Gilead Sciences
Pharmstandard
Fujifilm Holdings
Zhejiang Hisun Pharmaceutical Co. Ltd
Roche
Sanofi
Pfizer
Eli Lilly